Yellowstone Biosciences
About
Yellowstone Biosciences is a biotechnology company advancing a novel class of cancer immunotherapies based on soluble bispecific T cell receptor (TCR) therapeutics. Our platform leverages clinically validated, non-subclonal peptide-HLA class II (pHLA-II) targets identified in patients with acute myeloid leukaemia (AML) who have been cured by allogeneic stem cell transplantation (allo-SCT). Yellowstone is pioneering the use of Class II HLA-restricted antigens to generate highly selective, off-the-shelf immune therapeutics with broad applicability in haematological malignancies and solid tumours.
LIFE SCIENCES
NETWORKING INTERESTS
Additional questions
NETWORKING/COLLABORATION INTERESTS?
Representatives
Research Scientist
Yellowstone Biosciences